Channing J. Der
University of North Carolina (UNC), Chapel Hill, USA
Channing J. Der is Sarah Graham Kenan Distinguished Professor at the University of North Carolina at Chapel Hill and Einstein Visiting Fellow at the Charité – Universitätsmedizin Berlin. He received his PhD from the University of California, Irvine and completed his postdoctoral studies at Harvard Medical School and the Dana-Farber Cancer Institute. Since his initial discovery of RAS oncogenes in human cancer in 1982, his research has centered on the study of RAS oncoproteins in cancer. His research has been funded by grants from the National Cancer Institute, Department of Defense, Lustgarten Foundation, Pancreatic Cancer Action Network and AACR. He is a member of the NCI RAS Working Group and he served previously on the NCI Board of Scientific Counselors and Frederick National Laboratory Advisory Committee. He currently serves on the scientific advisory boards and consultant for numerous pharmaceutical/biotech companies. He is currently a member of the Scientific and Medical Advisory Board of the Pancreatic Cancer Action Network and previously on the scientific advisory board of the Lustgarten Foundation. His honors include Fellow of the AAAS, the recipient of an NCI Outstanding Investigator Award, the Battle Distinguished Cancer Research Award, the Mentorship Award for Lifetime Achievement, the University of California, Irvine Distinguished Alumnus Award, and the Einstein BIH Visiting Fellow Award.
Channing J. Der is Sarah Graham Kenan Distinguished Professor at the University of North Carolina at Chapel Hill and Einstein Visiting Fellow at the Charité – Universitätsmedizin Berlin. He received his PhD from the University of California, Irvine and completed his postdoctoral studies at Harvard Medical School and the Dana-Farber Cancer Institute. Since his initial discovery of RAS oncogenes in human cancer in 1982, his research has centered on the study of RAS oncoproteins in cancer. His research has been funded by grants from the National Cancer Institute, Department of Defense, Lustgarten Foundation, Pancreatic Cancer Action Network and AACR. He is a member of the NCI RAS Working Group and he served previously on the NCI Board of Scientific Counselors and Frederick National Laboratory Advisory Committee. He currently serves on the scientific advisory boards and consultant for numerous pharmaceutical/biotech companies. He is currently a member of the Scientific and Medical Advisory Board of the Pancreatic Cancer Action Network and previously on the scientific advisory board of the Lustgarten Foundation. His honors include Fellow of the AAAS, the recipient of an NCI Outstanding Investigator Award, the Battle Distinguished Cancer Research Award, the Mentorship Award for Lifetime Achievement, the University of California, Irvine Distinguished Alumnus Award, and the Einstein BIH Visiting Fellow Award.
